The epidermal growth factor receptor axis: Support for a new target for oral premalignancy

Cancer Prevention Research

Volumn 3, Issue 7, 2010, Pages 797-799

  Rosin, Miriam P ^a   Califano, Joseph A ^b,c  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

CANCER RISK; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CHROMOSOME; GENE LOCUS; HIGH RISK POPULATION; HUMAN; IN SITU HYBRIDIZATION; LEUKOPLAKIA; MOUTH CANCER; MOUTH CARCINOMA; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; HUMANS; MOUTH NEOPLASMS; PRECANCEROUS CONDITIONS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77954725485     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0114     Document Type: Review

References (17)

1. Benchekroun MT, Saintigny P, Thomas SM, et al. Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res 2010;3:800-9.
2. Hirsch FR, Varella-Garcia M, Dziadziuszko R, et al. Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small-cell lung cancer. Clin Cancer Res 2008;14:6317-23.
3. Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescence in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008;26:3351-7.
4. Rosin MP, Lam WL, Poh C, et al. 3p14 and 9p21 loss is a simple tool for predicting second oral malignancy at previously treated oral cancer sites. Cancer Res 2002;62:6447-50. (Pubitemid 35364104)
5. Roblyer D, Kurachi C, Stepanek V, et al. Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res 2009;2:423-31.
6. Poh CF, MacAulay CE, Zhang L, Rosin MP. Tracing the "at-risk" oral mucosa field with autofluorescence: steps toward clinical impact. Cancer Prev Res 2009;2:401-4.
7. Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2:682-5.
8. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000;6:357-62.
9. Papadimitrakopoulou VA, Lee JJ, William WN, Jr., et al. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without β-carotene in oral premalignancy. J Clin Oncol 2009;27:599-604.
10. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32.
11. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006;24:4170-6.
12. Temam S, Kawaguchi H, El-Naggar AK, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007;25:2164-70.
13. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6. (Pubitemid 36025259)
14. Bentzen SM, Atasoy BM, Daley FM, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005;23:5560-7.
15. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
16. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-27.
17. Jimeno A, Tan AC, Coffa J, et al. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res 2008;68:2841-9.